Harvard Bioscience Inc
NASDAQ:HBIO
Intrinsic Value
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. [ Read More ]
The intrinsic value of one HBIO stock under the Base Case scenario is 5.76 USD. Compared to the current market price of 3.56 USD, Harvard Bioscience Inc is Undervalued by 38%.
Valuation Backtest
Harvard Bioscience Inc
Run backtest to discover the historical profit from buying and selling HBIO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Harvard Bioscience Inc
Current Assets | 49m |
Cash & Short-Term Investments | 4.3m |
Receivables | 20m |
Other Current Assets | 24.7m |
Non-Current Assets | 88.3m |
PP&E | 8.8m |
Intangibles | 73.1m |
Other Non-Current Assets | 6.5m |
Current Liabilities | 26.5m |
Accounts Payable | 5.6m |
Accrued Liabilities | 9.4m |
Other Current Liabilities | 11.6m |
Non-Current Liabilities | 37.8m |
Long-Term Debt | 30.7m |
Other Non-Current Liabilities | 7m |
Earnings Waterfall
Harvard Bioscience Inc
Revenue
|
112.3m
USD
|
Cost of Revenue
|
-45.9m
USD
|
Gross Profit
|
66.4m
USD
|
Operating Expenses
|
-64.1m
USD
|
Operating Income
|
2.3m
USD
|
Other Expenses
|
-5.7m
USD
|
Net Income
|
-3.4m
USD
|
Free Cash Flow Analysis
Harvard Bioscience Inc
HBIO Profitability Score
Profitability Due Diligence
Harvard Bioscience Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Harvard Bioscience Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
HBIO Solvency Score
Solvency Due Diligence
Harvard Bioscience Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Harvard Bioscience Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HBIO Price Targets Summary
Harvard Bioscience Inc
According to Wall Street analysts, the average 1-year price target for HBIO is 7.06 USD with a low forecast of 6.82 USD and a high forecast of 7.35 USD.
Ownership
HBIO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HBIO Price
Harvard Bioscience Inc
Average Annual Return | 6.08% |
Standard Deviation of Annual Returns | 59% |
Max Drawdown | -75% |
Market Capitalization | 154.5m USD |
Shares Outstanding | 43 421 300 |
Percentage of Shares Shorted | 1.58% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.
Contact
IPO
Employees
Officers
The intrinsic value of one HBIO stock under the Base Case scenario is 5.76 USD.
Compared to the current market price of 3.56 USD, Harvard Bioscience Inc is Undervalued by 38%.